Check eligibility

Complete a 2-3 mins consultation form.

Start your consultation
Zepbound® KwikPen®
Zepbound® KwikPen®
Zepbound® KwikPen®
Zepbound® KwikPen®
Zepbound® KwikPen®
Zepbound® KwikPen®
Zepbound® KwikPen®

Vendor:Eli Lilly

Zepbound® KwikPen®

$299.00
Strength
Strength: 2.5 mg

All the power of tirzepatide in a refillable pen with a hidden needle and a single press to dose.

FDA-approved GLP-1 treatment

Reviewed by licensed US providers

Fast, discreet delivery and ongoing support
Start consultation
Our customers say Excellent Rated 4.7 Trustpilot Trustpilot

Quick summary

Type of Medicine

Once weekly injectable acting on the GLP-1 and GIP hormones for weight management

Generic

No

Active Ingredient

Tirzepatide, delivered through a refillable multidose KwikPen

Effective Within

Hunger usually eases in the opening fortnight, with the most noticeable weight change arriving once you reach a maintenance dose after a month or two.

Works By

Switches on the GLP-1 and GIP hormones together, easing hunger and slowing how fast the stomach empties.

Side Effects

Most people notice queasiness, looser or firmer stools and early fullness while the dose climbs. Persistent severe abdominal pain should always be checked, as pancreatitis is an uncommon risk.

Wegovy® pen or pill?

Zepbound® KwikPen®

Eli Lilly

Zepbound® KwikPen®
From $299.00
Foundayo Tablets

Eli Lilly

Foundayo Tablets
From $149.00
Zepbound® Pen

Eli Lilly

Zepbound® Pen
$1,245.00
How it’s taken

One weekly shot with one pen a month

One tablet a day

One weekly shot with one pen a week.

Average weight loss

Lose around 20–21% of body weight*

Lose around 11% of body weight*

Lose around 20–21% of body weight*

Best for

People who prefer a weekly routine

People who prefer no needles

People who prefer a weekly routine

How to take it

Inject under the skin using a pre-filled pen. The same pen has 4 doses for 4 weeks.

Take on an empty stomach with water

Inject under the skin using a pre-filled pen.

Payment method

Cash-pay only

Cash-pay only

Cash-pay or insurance might be available

View product
View product
View product

How it works

From question to doorstep, in days not weeks.

Get started

Product details

The KwikPen offers the same medicine that has reshaped obesity care, tirzepatide, in a format built around everyday convenience. Where the standard pen is a single dose, the KwikPen is a multidose device with the needle kept out of view and a single press to deliver each dose.

Tirzepatide works by switching on two of the gut hormones that govern appetite and fullness, GLP-1 and GIP. For many people that means less preoccupation with food, smaller portions without the constant battle, and weight that comes down at a steady, sustainable pace.

It is given once a week beneath the skin. The dose is raised in small steps over the opening weeks, a deliberate approach that keeps the stomach settled while the body grows used to the medicine.

  • A multidose pen with a concealed needle and one press per dose
  • Suits people who prefer fewer devices to handle and store
  • Built up gradually so tolerability stays in your control

Because tirzepatide carries a boxed warning about a rare thyroid tumor observed in animals, it should not be used by anyone with a personal or family history of medullary thyroid cancer or MEN 2. Prescription only.

Dial and deliver one weekly dose under the skin of the abdomen, thigh or upper arm using the KwikPen, rotating the site each week. Hold the pen in place for the full count after pressing so the whole dose is given. Build the dose up gradually as directed. If more than four days late, skip the missed dose and continue as normal. Store as instructed and never double up.

Tirzepatide as the active ingredient, in a sterile solution for injection.

Queasiness, looser or firmer stools and early fullness are common during dose increases and tend to settle. Gallbladder issues, pancreatitis and low blood sugar alongside diabetes medicines are less common. Mild redness at the injection site can happen.

Carries the GLP-1 class boxed warning for a rare thyroid tumor seen in animals. Avoid if you or a relative has had medullary thyroid cancer or MEN 2. Persistent severe abdominal pain needs prompt assessment for pancreatitis. Do not use in pregnancy.

Your success is worth celebrating

Real people. Real progress. Real support.

Check your Eligibility
Check your Eligibility
Check your Eligibility
Check your Eligibility
Check your Eligibility
Check your Eligibility
Check your Eligibility

FAQs

How is the KwikPen different from the single dose pen?

The medicine is identical. The KwikPen is a refillable multidose device with a hidden needle and a single press per dose, which some people find easier to handle and store.

How do I store it?

Keep it refrigerated until first use and follow the storage window printed on the pen once in use. Let it sit briefly before injecting so it is not cold.

What if I miss my weekly dose?

If it has been four days or less, take it when you remember. If longer, skip it and resume your usual day. Never take two doses close together.

How should Zepbound be stored?

Zepbound should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep the pen in its original packaging to protect from light. Once in use, it may be kept at room temperature for 30 days.

What is the difference between Wegovy and Zepbound?

Wegovy and Zepbound are both injectable medications used primarily for weight management in adults, but they differ in their active ingredients and mechanisms of action.

Wegovy:

Active Ingredient: Semaglutide.
Mechanism of Action: Wegovy functions as a GLP-1 receptor agonist, mimicking the action of the glucagon-like peptide-1 hormone which regulates appetite and calorie intake. It enhances feelings of fullness and reduces hunger, leading to a reduction in food intake.
Usage: Approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia.

Zepbound:

Active Ingredient: Tirzepatide.
Mechanism of Action: Zepbound is unique in that it acts as both a GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. This dual action not only helps in reducing appetite and food intake like GLP-1 agonists but also enhances insulin secretion in a glucose-dependent manner and possibly affects fat metabolism.
Usage: Initially approved for the treatment of type 2 diabetes, with promising results in significant weight reduction, leading to its approval for use in obesity management as well.

While both medications are part of a broader category of drugs used for metabolic management, the dual mechanism of Zepbound may offer broader metabolic effects compared to Wegovy. Both have shown effectiveness in weight loss and improvements in various metabolic parameters in clinical trials, but the choice between them may depend on individual health profiles, specific medical conditions, and healthcare provider recommendations.

Didn’t find your answer?

Don't hestitate to contact us